2Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet, 1998,351:1451.
3Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HEB2-positive breast cancer. N Engl J Med, 2005, 353: 1673-1684.
4Bhalla K, Harris WB. Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer. Semin Oncol, 1998, 25 (2 suppl 3): 19-24.
5Kuerer HM, Newman LA, Buzder AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg, 1998, 176:502-509.
6Ellis P, Smith I, Ashley S, et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol, 1998, 16:107-114.
7Cameron DA, Anderson ED, Levack P, et al. Primary systemic therapy for operable breast cancer - 10 - year survival data after chemotherapy and hormone therapy. Br J Cancer, 1997, 76:1099-1105.
8Pierga JY, Mouret E, Dieras V, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer, 2000, 83: 1480-1487.
9Hutcheon AW, Heys SD, Miller ID, et al. Improvements in survival in patients receiving primary chemotherapy with docetaxel for breast cancer: a randomised controlled trial. Breast Cancer Res Treat, 2001, 69: 298.
10Chang J, Ormerod M, Powles TJ, et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer, 2000, 89: 2145-2152.
1Keller LM ,Sopka DM,Li T,et al. Five-year results of whole breast in- tensity modulated radiation therapy for the treatment of early stage breast cancer: the Fox Chase Cancer Center experience [ J ]. Int J Radiat Oncol Biol Phys,2012,84(4) :881 -887.
